Cardioprotective effects of PCSK9 inhibitor evolocumab against doxorubicin-trastuzumab sequential treatment: The role of MYD88/NFKB/MTORC pathways

Category Primary study
JournalGiornale Italiano di Cardiologia
Year 2020
This article has no abstract
Epistemonikos ID: 52d1db0f38c79c5caa8a6870a501317b32b709d5
First added on: Feb 12, 2025